LOS ANGELES, CA – VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has announced a significant development milestone: its VXA-222 bispecific antibody-drug conjugate (bsADC) program has advanced beyond the discovery phase and into the next stage of development. This progress follows the successful completion of the discovery portion of VERAXA's collaboration with OmniAb Inc., which began in May 2025. With this milestone, VERAXA will now focus on engineering the final bispecific ADC candidate by combining the antibody binders identified through the collaboration with its proprietary antibody engineering, linker, and conjugation technologies.
The VXA-222 program is notable because, while it is not based on VERAXA's BiTAC platform, it leverages the company's proprietary technologies and represents one of its more advanced development programs. The advancement of VXA-222 underscores VERAXA's commitment to addressing difficult-to-treat cancers through a diversified oncology pipeline that includes bispecific antibody-drug conjugates, T-cell engagers, and engineered antibody formats.
In addition to the program milestone, VERAXA has expanded its intellectual property portfolio with its first BiTAC-related patent filings, along with additional patents supporting conjugation chemistry, payloads, and antibody technologies. The company now holds more than 50 granted owned or exclusively licensed patents across 26 patent families in 14 countries. Newly filed applications are expected to extend protection into at least 2047, providing a robust foundation for its innovative therapies.
The expansion of VERAXA's patent portfolio is crucial for protecting its next-generation antibody technologies and ensuring commercial viability. This intellectual property strength is vital for attracting potential partners and investors, as it reduces the risk of competitive infringement and secures a competitive edge in the rapidly evolving field of cancer therapeutics.
The advancement of VXA-222 and the expansion of the patent portfolio are expected to have significant implications for the biotech industry and for patients. For the industry, VERAXA's progress demonstrates the potential of bispecific ADCs as a powerful modality in oncology, combining the targeting capabilities of antibodies with the potent cell-killing effects of cytotoxic drugs. This could spur further innovation and investment in similar approaches.
For patients, the development of VXA-222 and other programs in VERAXA's pipeline offers hope for more effective and targeted treatments for cancers that are currently difficult to treat. The company's focus on engineered antibody formats aims to improve therapeutic efficacy while minimizing side effects, potentially leading to better outcomes and quality of life for patients.
VERAXA continues to build a diversified oncology pipeline, and the recent milestones reflect its strategic approach to advancing novel cancer therapies. The company's collaboration with OmniAb has been instrumental in identifying high-quality antibody binders, and VERAXA's proprietary technologies are designed to optimize the final therapeutic candidates. As VERAXA moves forward, it remains dedicated to delivering innovative treatments that address unmet medical needs in oncology.
The company's progress is also supported by its robust intellectual property strategy, which is critical in the competitive biotech landscape. By securing patents across multiple jurisdictions, VERAXA is positioning itself for long-term success and potential commercialization of its therapies.
Investors and industry observers will be watching VERAXA's next steps closely, as the company advances VXA-222 and other programs through preclinical and clinical development. The successful progression of these programs could lead to significant value creation and, ultimately, new treatment options for patients battling cancer.
For more information about VERAXA and its pipeline, visit the company's newsroom at https://ibn.fm/VRXA. Forward-looking statements in this article are based on current expectations and are subject to risks and uncertainties, as detailed in the company's filings with the SEC.
